BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 28619772)

  • 1. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
    Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
    BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta.
    Campos NG; Scarinci IC; Tucker L; Peral S; Li Y; Regan MC; Sy S; Castle PE; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1114-1121. PubMed ID: 33771846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
    Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
    Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
    Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Different Management Strategies for Detection CIN2+ of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) Pap Smear in Thailand.
    Tantitamit T; Termrungruanglert W; Oranratanaphan S; Niruthisard S; Tanbirojn P; Havanond P
    Asian Pac J Cancer Prev; 2015; 16(16):6857-62. PubMed ID: 26514457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
    Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
    Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
    Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
    Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.
    Perkins RB; Langrish SM; Stern LJ; Burgess JF; Simon CJ
    Womens Health Issues; 2010; 20(1):35-42. PubMed ID: 19944623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.
    Vanni T; Legood R; Franco EL; Villa LL; Luz PM; Schwartsmann G
    Int J Cancer; 2011 Aug; 129(3):671-9. PubMed ID: 20886598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.